1999 Fiscal Year Final Research Report Summary
NUCLEOTIDE SEQUENCE ANALYSES OF TRANSITIONAL CELL-SPECIFIC PROTEINS, UROPLAKINS, AND CLINICAL APPLICATION
| Project/Area Number |
10671469
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Shiga University of Medical Science |
|---|
Principal Investigator |
YOSHIKI Tatsuhiro Shiga University of Medical Science, Faculty of Medicine, The Department of Urology, Assistant Professor, 医学部, 講師 (80230704)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KATAOKA Akira Shiga University of Medical Science, Faculty of Medicine, The Department of Urology, Assistant, 医学部, 助手 (80293835)
KIM Chol-jang Shiga University of Medical Science, Faculty of Medicine, The Department of Urology, Assistant, 医学部, 助手 (10204968)
HAYASHIDA Hideshi Shiga University of Medical Science, Faculty of Medicine, The Department of Urology, Assistant, 医学部, 助手 (20173049)
MAKIURA Yaeko Shiga University of Medical Science, Faculty of Medicine, The Department of Anesthesiology, Assistant, 医学部, 助手 (90293836)
|
|---|
| Project Period (FY) |
1998 – 1999
|
| Keywords | uroplakin / transitional cell / PCR / cDNA / nucleotide sequence |
|---|
| Research Abstract |
Uroplakins (UPs), urothelium-specific transmembrane proteins, are present only in urothelia and may be good candidates as tumor markers specific for transitional cell carcinomas (TCC). A partial nucleotide sequence of human UP-II gene cDNA and the complete nucleotide sequence of human UP-Ib and UP-III had been determined to prepare the UPs -specific primers for RT-PCR. We investigated the expression of UP-Ia, Ib, UP-II or III genes in the tissues and peripheral blood of 12 patients with TCC. HT1197, a TCC cell line, was used as an indicated cell line to assess a detection system for the UP-Ib, II or III gene-expressing cancer cell could be detected in 5mL peripheral blood. UP genes were expression in both cancerous and noncancerous urothelia taken from all patients examined by RT-PCR. UP-Ib, II or III gene-expression was detected in the peripheral blood from 3 of 3 patients with metastatic TCC but not from 9 patients with non-metastatic TCC nor 3 healthy volunteers. UPs may be employed as good tumor markers for transitional cell cancer, because they are highly conserved and expressed well, not only in non-cancerous cells but also in cancer cells. Furthermore, detection of UP genes-expression in blood by nested RT-PCR may provide helpful information in the diagnosis and management of TCC.
Polyclonal and monoclonal antibodies against UPs were generated using synthesized polypeptides and recombinant protein, respectively, as immunogens. Antibodies against both UP-Ia and UP-Ib reacted with the cell membrane of TCCs. We are currently expanding an immunohistochemical study by targeting a larger number of patients to examine the clinical usefulness of these antibodies.
|
